According to Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC, professor of medicine at the Hofstra Northwell School of Medicine, research on rivaroxaban to prevent thrombosis is moving from determining efficacy to evaluating patient-centered outcomes in a variety of clinical situations, as evidenced by new studies like EINSTEIN-CHOICE and the MARINER trial.
According to Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC, professor of medicine at the Hofstra Northwell School of Medicine, research on rivaroxaban to prevent thrombosis is moving from determining efficacy to evaluating patient-centered outcomes in a variety of clinical situations, as evidenced by new studies like EINSTEIN-CHOICE and the MARINER trial.
Transcript (slightly modified)
What are the objectives of your ongoing research, the MARINER trial?
Looking at a strategy of extended thromboprophylaxis with rivaroxaban, this time compared with placebo, in high-risk, medically ill patients. This likely at the end will be the largest trial of its kind, of extended thromboprophylaxis in medically ill. It’s using symptomatic endpoints. It’s using also very up-to-date, very innovative risk assessment strategies, namely a validated risk assessment model, the IMPROVE model, as well as a recently valuated biomarker, the d-dimer, in identifying patients with high-risk features.
I think importantly with MARINER, we are using symptomatic, what we call patient-centric outcomes, such as symptomatic DVT [deep vein thrombosis], symptomatic PE [pulmonary embolism, and VT-related [venous thromboembolism] death as an outcome, so we’re using those outcomes for the first time.
What do studies like EINSTEIN-CHOICE signify about the future directions of thrombosis research?
I think what we’re seeing more and more is, again, we’re gaining ground with respect to both efficacy and now safety with direct oral anticoagulants, specifically rivaroxaban, in now many clinical scenarios and clinical situations, so a trial like EINSTEIN-CHOICE really just starts expanding our choices and our momentum with respect to treatment of these patient groups.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More